AUR-112
/ Dr. Reddy’s
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 27, 2025
ADITI-1: Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Lymphoma • Oncology
January 04, 2025
ADITI-1: Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited
New P1 trial • Hematological Malignancies • Lymphoma • Oncology
1 to 2
Of
2
Go to page
1